熱門資訊> 正文

安进、阿斯利康获得FDA批准收购Tezspire

2025-10-18 04:22

Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) said that the FDA has approved Tezspire as a maintenance treatment for chronic rhinosinusitis with nasal polyps in patients aged 12 and older.
This FDA approval is supported by data demonstrating the drug's efficacy and safety from the WAYPOINT Phase III clinical trial.
Additionally, applications for regulatory approval are currently being evaluated in Europe, China, Japan, and various other nations.

More on Amgen, AstraZeneca

AstraZeneca: Oncology Breakthroughs And Farxiga Surge Excite Investors
Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition
Amgen: Imdelltra Could Be The Next Game Changer
Astra, GSK up after report on U.K. – U.S. drug pricing deal
AstraZeneca reports positive data from Imfinzi's bladder cancer trial

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。